Business Wire

42nd President of the United States, Bill Clinton, to Deliver Keynote at Everbridge COVID-19: Road to Recovery (R2R) Executive Summit, May 26-27, 2021

Share

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced 42nd President of the United States Bill Clinton as its first keynote for the Spring 2021 COVID-19: Road to Recovery (R2R) virtual leadership summit to be held May 26-27. The two-day global symposium addresses resilience strategies and best practices as global businesses, governments and economies seek recovery and a return to normalcy from the ongoing coronavirus pandemic. Attendees will hear presentations from world leaders, health experts and C-suite executives from cross-industry and geography.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005211/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

42nd President of the U.S., Bill Clinton, to Deliver Keynote at Everbridge COVID-19: Road to Recovery (R2R) Executive Summit (Graphic: Business Wire)

The Everbridge symposium series, which kicked off in 2020, offers global leaders a valuable forum to exchange views on how to safely reopen economies and restore the ability for people to return to schools, offices and other public spaces. Speakers and participants represent all sectors of society from business and government, community organizations and advocacy groups, to science, medicine, transportation, entertainment, and academia.

“By bringing together the brightest minds in government and business, along with top health experts from around the world, our 2021 COVID-19: Road to Recovery symposium tackles the complex challenges and best practices required to help solve this public health crisis faster – from efficient distribution of a vaccine to safely returning people to work and re-opening economies,” said David Meredith, CEO of Everbridge. “With the establishment of the Clinton Foundation and President Clinton’s commitment to matters of global health and economic recovery, we welcome his important perspective and proven leadership on solutions for improving the lives of people around the world.”

As the 42nd president of the United States, President Clinton served two terms from 1993 to 2001. Under his leadership, the country enjoyed the strongest economy in a generation and the longest economic expansion in U.S. history, including the creation of more than 22 million jobs. After leaving the White House, President Clinton established the Clinton Foundation with the mission to improve global health, strengthen economies, promote health and wellness, and protect the environment. In addition to his Foundation work, President Clinton has served as the top United Nations envoy for the Indian Ocean tsunami recovery effort and as the UN Special Envoy to Haiti. Today, the Clinton Foundation is supporting economic growth, capacity building, and education in Haiti.

Last year, Everbridge welcomed President George W. Bush, Anthony Fauci, MD, Scott Gottlieb, MD, Dr. Sanjay Gupta, MD, U.S. General Colin L. Powell, USA (Ret.), and Virgin Group Founder Sir Richard Branson, among others, to serve as keynote speakers. The events attracted more than 40,000 participants including government officials, healthcare experts and senior executives from 150 countries, as well as participants from the Centers for Disease Control and Prevention, the Mayo Clinic, Goldman Sachs, Fannie Mae, Ford Motor Company, Humana, IBM, and others.

To register for the Everbridge Spring 2021 COVID-19 R2R: The Road to Recovery Symposium, click here.

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,600 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication modalities, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 20 cities around the globe. For more information visit www.everbridge.com

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 26, 2021. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Everbridge Contacts:
Jeff Young
Media Relations
jeff.young@everbridge.com
781-859-4116

Joshua Young
Investor Relations
joshua.young@everbridge.com
781-236-3695

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 06:25:00 EET | Press release

FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,

Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 05:31:00 EET | Press release

A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig

OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 04:00:00 EET | Press release

Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl

Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date8.1.2026 23:30:00 EET | Press release

The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/ Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation). The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Citation CJ3 Gen2 deliv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye